for orders over $200
Andarine, also known as S4, belongs to the class selective androgen receptor modulator (SARM). It interacts with androgen receptors in bone and muscles and promotes muscle growth and enhances bone density. It was first developed by GTx, Inc. for the treatment of benign prostatic hypertrophy (BPP) and degenerative musculoskeletal diseases.
Andarine is a non-steroidal SERM that doesn’t cause traditional side effects associated with steroidal use. In addition to BPP, it has also been studied for its effect on fertility, erythropoiesis and sexual libido in men and women. Further, it is a popular drug among fitness coaches and sports players as a performance-boosting agent. It is an investigational drug that has not yet been approved by FDA. At Element SARMS, andarine S4 for sale is restricted to educational and research purposes.
IUPAC Name: (2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamideSynonyms: 401900-40-1, GTX-007, S-4 cpd Molecular Formula: C19H18F3N3O6Molecular Weight: 441.4 g/mol CAS number: 401900-40-1PubChem CID: 9824562
Studies show that andarine has a selective anabolic effect as compared to testosterone, with a minor effect on prostate muscles.
In one study, researchers assessed the effect of S4 on the skeletal muscles in castrated male rats. Castration in animals leads to a decrease in androgen as they no longer produce it because of disruption in the primary mechanism. After twelve weeks of castration, subjects received either S4, testosterone or a placebo. Researchers found that the treatment group observed restoration in mass and strength of the soleus muscle, as well as the levator ani muscle, as compared to the levels in intact animals.
Further, researchers found that subjects treated with dihydrotestosterone had a 2-fold greater effect on prostate and seminal vesicle weight. While S4 only had a little effect (only 16 to 17%) as compared to the control group . One more study found that S4 andarine has a selective activity as it stimulated anabolic organs more prominently as compared to androgenic tissues. Further, it revealed that the anabolic activity of S4 was similar to or greater than that of testosterone propionate .
Andarine S4 has been shown to improve fat loss. One study in ovariectomized rats found that S4 treatment resulted in significant fat loss . This effect might be achieved by the anabolic effect of S4 on muscle mass. As muscle mass increases, the metabolic rate also accelerates which causes the body to burn more fat and cause an increase in energy expenditure.
Androgen has been known to have protective effects on skeletal muscles. Several studies on animal models investigated the effect of selective estrogen receptor modulators on bone density. One study found that S4 treatment maintained the trabecular bone mineral density and bone strength in rats with ovariectomy. Removal of ovaries is associated with decreased levels of estrogen that contribute to bone loss .
Similarly, researchers assessed the effect of andarine treatment on bone in an osteopenic model using aged female rats. Results found that S4 administration resulted in improved bone mineral density and bone cortical quality, thus enhancing load-bearing capacity. This data suggests that S4 could be used as a potential treatment for osteoporosis as it promotes bone anabolism, prevents bone resorption and increases muscle mass .
Research shows that Andarine S4 might have antitumor properties. One study found that andarine exhibits anticancer activity by repressing cell growth and differentiation via cell cycle arrest at G0/G1 phase. Further, it downregulates the expression of CDKN1A which plays a role in regulating cell cycle and proliferation .
Another study evaluated the anticarcinogenic effects of andarine on lung cancer. The researchers reported that S4 inhibited cell growth, migration and proliferation while inducing apoptosis. Further, it suppressed the expression of certain genes that exhibit antitumor activity . Similarly, researchers found that it inhibits hepatocellular carcinoma (HCC) by inhibiting PI3K/AKT/mTOR, a frequently activated pathway that contributes to the severity of HCC .
Andarine S4 was developed for the treatment of benign prostatic hyperplasia. It is classified as an investigational drug and hasn’t received approval from FDA till now. We need more research on humans to confirm its safety and efficacy. Till then, Andarine S4 purchase is only available for FDA-approved research and educational purposes. Ready to take your research to the next level? Buy Andarine S4 from Element Sarms and make significant strides.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.